LEP and metabolic dysfunction-associated steatotic liver disease: Ameliorate NAFLD with IR by decreasing hypertriglyceridemia, hyperglycemia and hyperinsulinemia; up-regulating the mRNA expression of adiponectin and down-regulating the leptin mRNA expression in liver